HIV‐1 Load Quantitation: A 17‐Year Perspective | Zendy

Mark Holodniy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

HIV‐1 Load Quantitation: A 17‐Year Perspective

Author(s) -

Mark Holodniy

Publication year - 2006

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/505352

Subject(s) - viral load , human immunodeficiency virus (hiv) , surrogate endpoint , medicine , clinical trial , clinical practice , immunology , intensive care medicine , virology , physical therapy

During the past decade and a half, quantitation of plasma-associated human immunodeficiency virus type 1 (HIV-1) RNA level, or HIV-1 load, has been validated in clinical practice and clinical trials as an important surrogate marker of HIV-1 disease progression and of the potency and durability of antiretroviral regimens. This review highlights some of the history, accomplishments, and impact of Tom Merigan's laboratory on the use of HIV-1 load as a marker, as well as on updating technologies for determining HIV-1 load, their performance, interpretation of the results, and their use in clinical practice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research